Suppr超能文献

重组人趋化因子CCL2在卵巢癌中的纯化及其功能

Purification of recombinant human chemokine CCL2 in and its function in ovarian cancer.

作者信息

Liu Wei, Wang Lei, Zhang Jiajia, Qiao Liuhui, Liu Yiqing, Yang Xinke, Zhang Jinghua, Zheng Wenming, Ma Zhenling

机构信息

College of Life Sciences, Henan Agricultural University, Zhengzhou, 450002 China.

出版信息

3 Biotech. 2021 Jan;11(1):8. doi: 10.1007/s13205-020-02571-0. Epub 2021 Jan 2.

Abstract

UNLABELLED

Chemokine (CC-motif) ligand 2 (CCL2) is an inflammatory cytokine that regulates the infiltration and migration of monocytes. It is highly expressed by both tumor and stromal cells and has been associated with tumorigenesis. However, the effect of the exogenous administration of CCL2 on ovarian cancer remains largely unknown. In this report, we attempted to establish an expression system in to produce recombinant hCCL2. The recombinant plasmid containing the hCCL2 cDNA was prepared using the prokaryotic-expression plasmid pGEX-5X-3 and transformed into BL21. GST-hCCL2 was successfully induced by 0.1 mmol/L IPTG at 20 °C for 6 h, and the recombinant protein was purified using affinity chromatography. The purified protein was identified by SDS-PAGE and Western Blot. In vitro experiments revealed that rhCCL2 promoted the proliferation of ovarian cancer cells and increased the levels of phosphorylation of MEK and ERK1/2, and the levels of JUN, RELB and NF-κB2 mRNA. Furthermore, inhibition of ERK signaling by treatment with PD98059 decreased ovarian cancer cell proliferation and levels of JUN, RELB, and NF-κB2 mRNA, indicating that exogenous rhCCL2 increased the proliferation of ovarian cancer cells, partially by activating the MAPK/ERK pathway, and by targeting JUN, RELB, and NF-κB2. Our study uncovered a promoting role of exogenous CCL2 on ovarian cancer cell proliferation through the MAPK/ERK signaling pathway, which may facilitate the discovery of more potential roles of CCL2 in ovarian cancer.

SUPPLEMENTARY INFORMATION

The online version contains supplementary material available at 10.1007/s13205-020-02571-0.

摘要

未标记

趋化因子(CC基序)配体2(CCL2)是一种调节单核细胞浸润和迁移的炎性细胞因子。它在肿瘤细胞和基质细胞中均高表达,且与肿瘤发生有关。然而,外源性给予CCL2对卵巢癌的影响在很大程度上仍不清楚。在本报告中,我们试图建立一个表达系统来生产重组人CCL2。使用原核表达质粒pGEX-5X-3制备含有人CCL2 cDNA的重组质粒,并将其转化到大肠杆菌BL21中。在20℃用0.1 mmol/L异丙基-β-D-硫代半乳糖苷(IPTG)成功诱导6小时表达GST-hCCL2,并用亲和层析法纯化重组蛋白。通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)和蛋白质免疫印迹法(Western Blot)鉴定纯化后的蛋白质。体外实验表明,重组人CCL2促进卵巢癌细胞增殖,并增加丝裂原活化蛋白激酶激酶(MEK)和细胞外信号调节激酶1/2(ERK1/2)的磷酸化水平,以及原癌基因c-Jun、原癌基因RelB和核因子κB2(NF-κB2)信使核糖核酸(mRNA)的水平。此外,用PD98059处理抑制ERK信号通路可降低卵巢癌细胞增殖以及c-Jun、RelB和NF-κB2 mRNA的水平,表明外源性重组人CCL2部分通过激活丝裂原活化蛋白激酶/细胞外信号调节激酶(MAPK/ERK)通路并以c-Jun、RelB和NF-κB2为靶点来增加卵巢癌细胞的增殖。我们的研究揭示了外源性CCL2通过MAPK/ERK信号通路对卵巢癌细胞增殖具有促进作用,这可能有助于发现CCL2在卵巢癌中更多的潜在作用。

补充信息

在线版本包含可在10.1007/s13205-020-02571-0获取的补充材料。

相似文献

1
Purification of recombinant human chemokine CCL2 in and its function in ovarian cancer.
3 Biotech. 2021 Jan;11(1):8. doi: 10.1007/s13205-020-02571-0. Epub 2021 Jan 2.
2
Expression and purification of recombinant human CCL5 and its biological characterization.
Protein J. 2022 Apr;41(2):337-344. doi: 10.1007/s10930-022-10047-8. Epub 2022 May 7.
3
Exogenous interleukin-1 beta promotes the proliferation and migration of HeLa cells via the MEK/ERK signaling pathway.
Mol Biol Rep. 2022 May;49(5):3765-3772. doi: 10.1007/s11033-022-07216-4. Epub 2022 Mar 17.
4
Soluble overexpression and purification of bioactive human CCL2 in E. coli by maltose-binding protein.
Mol Biol Rep. 2015 Mar;42(3):651-63. doi: 10.1007/s11033-014-3812-3. Epub 2014 Nov 13.
10
[Expression and significance of MAPK/ERK in the specimens and cells of epithelial ovarian cancer].
Zhonghua Fu Chan Ke Za Zhi. 2019 Aug 25;54(8):541-547. doi: 10.3760/cma.j.issn.0529-567x.2019.08.007.

引用本文的文献

1
CC Chemokine 2 Promotes Ovarian Cancer Progression through the MEK/ERK/MAP3K19 Signaling Pathway.
Int J Mol Sci. 2023 Jun 26;24(13):10652. doi: 10.3390/ijms241310652.
2
Role of CC-chemokine ligand 2 in gynecological cancer.
Cancer Cell Int. 2022 Nov 19;22(1):361. doi: 10.1186/s12935-022-02763-z.
3
CC Chemokine Ligand-2: A Promising Target for Overcoming Anticancer Drug Resistance.
Cancers (Basel). 2022 Aug 31;14(17):4251. doi: 10.3390/cancers14174251.
4
MCP-1 targeting: Shutting off an engine for tumor development.
Oncol Lett. 2022 Jan;23(1):26. doi: 10.3892/ol.2021.13144. Epub 2021 Nov 19.
5
Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting.
Cell Prolif. 2021 Oct;54(10):e13115. doi: 10.1111/cpr.13115. Epub 2021 Aug 31.

本文引用的文献

1
Purification of insoluble GST-fused and GST-cleaved Cav1.2 channel fragment by denaturation and renaturation.
Protein Expr Purif. 2019 Aug;160:7-10. doi: 10.1016/j.pep.2019.03.013. Epub 2019 Mar 26.
2
The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally?
Cell Mol Immunol. 2018 Apr;15(4):335-345. doi: 10.1038/cmi.2017.135. Epub 2018 Jan 29.
3
A highly efficient ligation-independent cloning system for CRISPR/Cas9 based genome editing in plants.
Plant Methods. 2017 Oct 16;13:86. doi: 10.1186/s13007-017-0236-9. eCollection 2017.
4
A critical role of periostin in B-cell acute lymphoblastic leukemia.
Leukemia. 2017 Aug;31(8):1835-1837. doi: 10.1038/leu.2017.149. Epub 2017 May 22.
5
CCL2/Monocyte Chemoattractant Protein 1 and Parathyroid Hormone Action on Bone.
Front Endocrinol (Lausanne). 2017 Mar 29;8:49. doi: 10.3389/fendo.2017.00049. eCollection 2017.
6
The production of monocyte chemoattractant protein-1 (MCP-1)/CCL2 in tumor microenvironments.
Cytokine. 2017 Oct;98:71-78. doi: 10.1016/j.cyto.2017.02.001. Epub 2017 Feb 8.
8
Recombinant cloning strategies for protein expression.
Curr Opin Struct Biol. 2016 Jun;38:145-54. doi: 10.1016/j.sbi.2016.06.010. Epub 2016 Jul 5.
9
Overview of Fusion Tags for Recombinant Proteins.
Biochemistry (Mosc). 2016 Mar;81(3):187-200. doi: 10.1134/S0006297916030019.
10
Epilepsy, Seizures, and Inflammation: Role of the C-C Motif Ligand 2 Chemokine.
DNA Cell Biol. 2016 Jun;35(6):257-60. doi: 10.1089/dna.2016.3345. Epub 2016 May 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验